BridgeMD
Prevention study for Coronary Artery Disease
Official title Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
ClinicalTrials.gov ID: NCT05845489
What this study is testing
What is Clopidogrel treatment group?
Clopidogrel treatment group is an investigational medicine, given as an once-daily, being studied as a potential treatment for coronary artery disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The investigators will evaluate the efficacy and safety of clopidogrel for primary prevention in patients diagnosed with coronary atherosclerosis on imaging that did not require revascularization therapy. The trial will test the hypothesis that clopidogrel is beneficial in preventing major adverse cardiovascular and cerebrovascular events (MACCE) in patients with subclinical coronary atherosclerosis identified on imaging.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- Male or female aged ≥40 years
- Patients with subclinical coronary atherosclerosis identified from coronary CT angiography or coronary angiography within 2 years without clinical...
- Without significant coronary artery stenosis (Diameter stenosis \>50%), which needs revascularization
- Agreement to give written informed consent
You likely can't join if
- A history of a diagnosed cardiovascular or cerebrovascular disease (Type1 myocardial infarction, heart failure, peripheral artery disease, stroke...
- A history of coronary artery intervention or coronary artery bypass graft surgery, which needs chronic maintenance of antiplatelet therapy
- Absolute contraindication or allergy to clopidogrel
- Patients receiving anticoagulants for other comorbidities
- A history of Bleeding diathesis, known coagulopathy, or major bleeding, BARC class ≥3, resulting in the stop of antiplatelet agents
- Planned surgery or intervention which needs to stop antiplatelet agents ≥1 month
See the full eligibility criteria
- Male or female aged ≥40 years
- Patients with subclinical coronary atherosclerosis identified from coronary CT angiography or coronary angiography within 2 years without clinical events after an imaging study
- Without significant coronary artery stenosis (Diameter stenosis \>50%), which needs revascularization
- Agreement to give written informed consent
- A history of a diagnosed cardiovascular or cerebrovascular disease (Type1 myocardial infarction, heart failure, peripheral artery disease, stroke, transient ischemic attack, carotid artery stenosis\>50%, carotid artery...
- A history of coronary artery intervention or coronary artery bypass graft surgery, which needs chronic maintenance of antiplatelet therapy
- Absolute contraindication or allergy to clopidogrel
- Patients receiving anticoagulants for other comorbidities
- A history of Bleeding diathesis, known coagulopathy, or major bleeding, BARC class ≥3, resulting in the stop of antiplatelet agents
- Planned surgery or intervention which needs to stop antiplatelet agents ≥1 month
- Presence of non-cardiac comorbidity with life expectancy ≤ 5 years at randomization
- Females with pregnancy or breast-feeding
- Patients who are thought to be inappropriate for the trial based on physicians' decision
The study team makes the final eligibility decision.
Where it's taking place
- Seoul, Other, South Korea
- Andong, South Korea
- Busan, South Korea
- Changwon, South Korea
- Cheonan, South Korea
- Cheongju-si, South Korea
- Chuncheon, South Korea
- Daegu, South Korea
- Daejeon, South Korea
- Gangneung, South Korea
- Gwangju, South Korea
- Gyeonggi-do, South Korea
- Hwasun, South Korea
- Incheon, South Korea
- Jeju City, South Korea
- Jeonju, South Korea
- Jinju, South Korea
- Pohang, South Korea
- Sejong, South Korea
- Seoul, South Korea
+ 2 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seoul, Other, South Korea; Andong, South Korea; Busan, South Korea; Changwon, South Korea; Cheonan, South Korea; Cheongju-si, South Korea and 16 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.